Frontier Medicines Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
Frontier Medicines is a biotechnology research company focused on precision medicine, aiming to develop treatments against disease-causing proteins that have been difficult to target. The company leverages a discovery and development platform that integrates chemoproteomics, covalent drug discovery, and machine learning to advance therapies. Its lead program targets both the activated and inactive states of KRAS G12C, a cancer driver recognized in multiple tumor types. The company operates from facilities in South San Francisco, California and Boston, Massachusetts, situating it among major life sciences hubs on both coasts. In March 2026, Frontier Medicines announced an exclusive licensing agreement with LG Chem for FMC-220, a first-in-class covalent activator of p53 Y220C.